RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $330

Benzinga · 2d ago
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.